A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application, Prostaglandins, Leukotrienes and Essential Fatty Acids, 2014; 91(6) Immediately via their non-commercial personal homepage or blog by updating a preprint in arXiv or RePEc with the accepted manuscript via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group directly by providing copies to their students or to research collaborators for their personal use for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement After the embargo period via non-commercial hosting platforms such as their institutional repository via commercial sites with which Elsevier has an agreementIn all cases accepted manuscripts should: link to the formal publication via its DOI bear a CC-BY-NC-ND license -this is easy to do, click here to find out how if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article
AbstractConventional assays of omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) status in humans involve venous blood collection and expensive, multi-step processes that limit their usefulness as screening tools. This study aimed to develop a capillary dried blood spot (DBS) system capable of protecting n-3 LCPUFA from oxidation for up to 2 months at room temperature (20-25°C). We demonstrated that a DBS system comprising both an antioxidant and chelating agent on silica-gel coated paper prevented any significant change in the n-3 LCPUFA profile after 2 months. Our DBS assay was then tested in fifty subjects, and this demonstrated the presence of strong and significant correlations between the results obtained from the DBS system and those obtained from conventional measures for all fatty acids, in particular the n-3 LCPUFA EPA and DHA (r>0.96, P<0.0001). This study therefore validates our DBS system as a reliable method for the assessment of n-3 LCPUFA status in humans.